Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB) EBITDA (2023 - 2025)

Historic EBITDA for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to -$55.6 million.

  • Nuvation Bio's EBITDA fell 4419.0% to -$55.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$219.0 million, marking a year-over-year increase of 5849.16%. This contributed to the annual value of -$567.5 million for FY2024, which is 70968.26% down from last year.
  • Latest data reveals that Nuvation Bio reported EBITDA of -$55.6 million as of Q3 2025, which was down 4419.0% from -$59.9 million recorded in Q2 2025.
  • Nuvation Bio's EBITDA's 5-year high stood at -$10.3 million during Q4 2023, with a 5-year trough of -$462.6 million in Q2 2024.
  • Its 3-year average for EBITDA is -$74.0 million, with a median of -$38.6 million in 2024.
  • As far as peak fluctuations go, Nuvation Bio's EBITDA crashed by 199344.71% in 2024, and later soared by 8705.59% in 2025.
  • Over the past 3 years, Nuvation Bio's EBITDA (Quarter) stood at -$10.3 million in 2023, then tumbled by 387.51% to -$50.3 million in 2024, then dropped by 10.65% to -$55.6 million in 2025.
  • Its last three reported values are -$55.6 million in Q3 2025, -$59.9 million for Q2 2025, and -$53.3 million during Q1 2025.